Key result
Unmasked continuous glucose monitoring significantly reduced missed bolus doses compared to masked monitoring (0.62 vs 0.74 MBD/day, P=0.008) and improved time-in-range.
Why the study?
Does unmasked real-time CGM compared to masked CGM reduce missed bolus doses and improve time-in-range in people with type 1 and type 2 diabetes?
Does unmasked real-time CGM compared to masked CGM reduce missed bolus doses and improve time-in-range in people with type 1 and type 2 diabetes?
Unmasked real-time CGM significantly reduces missed bolus doses and improves time-in-range compared to masked CGM in patients with diabetes.
Unmasked CGM was associated with fewer missed boluses and better TIR in diabetes; hypothesis-generating pending randomized confirmation.
Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (TBR), and key participant characteristics in people with diabetes. Methods: This was a 12-week, single-arm, exploratory, two-period study for people with type 1 diabetes (T1D) or type 2 diabetes (T2D). The primary objective was to estimate the average number of MBD during masked and real-time CGM use. The secondary objective was to estimate the average percent TIR and its relationship to MBD. An exploratory objective was to investigate the participant characteristics that were associated with MBD. Data were analyzed for differences in MBD by diabetes type and other participant characteristics, by CGM period, and by hypoglycemic fear scores. Results: Participants ( n = 64; T1D, n = 38; T2D, n = 26) were 48 ± 11.9 years old and 44% were female. From the masked to the unmasked period, MBD, %TAR, %TBR, and glycated hemoglobin decreased significantly (0.74 MBD/day to 0.62 MBD/day, P = 0.008; 53.6%–48.1%, P = 0.004; 4.49%–2.93%, P < 0.001; mean 8.8%–8.4%, P < 0.001, respectively), while %TIR increased significantly (41.9%–49.0%, P < 0.001). MBD/day was negatively associated with TIR ( P = 0.016) and positively associated with TAR ( P = 0.015) for T1D and positively associated with TBR ( P = 0.024) for T2D in the masked period only. MBD was significantly associated with fear of hypoglycemia for T2D, but not T1D. Conclusions: MBD is associated with reduced TIR when CGM is masked and tailored therapeutic approaches are needed for T1D and T2D populations.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2021) studied Type 1 and Type 2 Diabetes (n=64). Unmasked continuous glucose monitoring (CGM) vs. Masked continuous glucose monitoring (CGM) was evaluated on Average number of missed bolus doses (MBD) per day (p=0.008). Unmasked continuous glucose monitoring significantly reduced missed bolus doses compared to masked monitoring (0.62 vs 0.74 MBD/day, P=0.008) and improved time-in-range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: